Saturday, July 11, 2026

Drug profile · INN

protokylol hydrochloride

protokylol hydrochloride (VENTAIRE) is a beta-2 adrenergic receptor agonist. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — protokylol hydrochloride
US status
approved
Class
Route
ORAL
Patents
0
Programs
0
Data quality
0.84

Quick answer

protokylol hydrochloride (VENTAIRE) is a beta-2 adrenergic receptor agonist. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN protokylol hydrochloride
Brand VENTAIRE
Mechanism Beta-2 adrenergic receptor agonist
Target Beta-2 adrenergic receptor
Route ORAL
Formulation TABLET

Mechanism of action

Beta-2 adrenergic receptor agonist

Primary target: Beta-2 adrenergic receptor

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. albuterol Beta-2 adrenergic receptor agonist
  2. albuterol sulfate Beta-2 adrenergic receptor agonist
  3. arformoterol tartrate Beta-2 adrenergic receptor agonist
  4. formoterol fumarate Beta-2 adrenergic receptor agonist
  5. isoetharine hydrochloride Beta-2 adrenergic receptor agonist
  6. levalbuterol hydrochloride Beta-2 adrenergic receptor agonist

Frequently asked questions

What is protokylol hydrochloride?

protokylol hydrochloride (VENTAIRE) is a beta-2 adrenergic receptor agonist. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for protokylol hydrochloride?

VENTAIRE is a marketed brand name for protokylol hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of protokylol hydrochloride?

protokylol hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.